EMN 2018

The 1st European Myeloma Network (EMN) Meeting 2018, held in Turin, Italy, took place on the 19–21 April. EMN 2018 hosted leading specialists in multiple myeloma (MM), who presented the latest research in this ever-evolving field.

Our coverage of this year’s conference includes a special interview with Robert Kyle about his work, which culminated in a much clearer understanding of the progression and risk factors for MM. Other highlights include advances in novel therapies and arguments for using patient fitness as a criterion for treatment rather than age.

Highlighted topics to explore include measurable residual disease, immunotherapy, transplantation and other monoclonal gammopathies, such as smoldering multiple myeloma, MGUS and amyloidosis. Watch those at the forefront of research cover these exciting topics right here.

Measurable Residual Disease

View all

4:23

MRD in myeloma: the complementary role of imaging techniques

Elena Zamagni • 19 Apr 2018

2:45

Predicting long-term outcomes in myeloma: MRD

Philip McCarthy • 19 Apr 2018

Immunotherapy

View all

2:19

Novel avenues for MM treatment: CAR T-cells, venetoclax, induction & MRD

Nikhil Munshi • 19 Apr 2018

2:45

Monoclonal antibodies: the arsenal against R/R MM

Niels van de Donk • 19 Apr 2018

150 Years of Multiple Myeloma Therapy

One of the most anticipated talks at this year’s conference was given by Robert Kyle, MD.

Prof. Kyle gives a detailed description of the history of MM, beginning with the first recorded case of the disease in the 1840’s and concluding with the developments over the years to treat this disease.